Black-box Warning

Five things for pharma marketers to know: Wednesday, October 5, 2016

Five things for pharma marketers to know: Wednesday, October 5, 2016

By

The FDA to require black-box warnings for hep.-C drugs; AstraZeneca's Brilinta fails to meet study goals; ICER says PD-1s are too pricey

OPINION

Email Newsletters